Skip to main content

Table 2 Refractory odds ratios for selected baseline characteristics in univariable and multivariable analyses

From: Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study

Baseline characteristics

Univariate analyses

Multivariate analysesa

Refractory, % (n/N)

OR (95% CI)

P value

OR (95% CI)

P value

Age, year

 ≥ 36

39.4 (65/165)

Reference

 

Reference

 

 < 36

59.1 (107/181)

2.2 (1.4–3.4)

< 0.001

1.7 (1.1–2.7)

0.024

Current smoking, n (%)

 Yes

61.1 (22/36)

1.7 (0.8–3.4)

0.152

  

 No

48.4 (150/310)

Reference

   

GO, n (%)

 Yes

65.9 (56/85)

2.4 (1.4–4.0)

0.001

2.5 (1.4–4.5)

0.002

 No

44.4(116/261)

Reference

 

Reference

 

Initial goiter size (cm3)

 ≥ 11.5

56.5 (160/283)

5.5 (2.8–10.8)

< 0.001

4.6 (2.2–9.5)

< 0.001

 < 11.5

19.0 (12/63)

Reference

 

Reference

 

Initial fT3 (pmol/L)

 ≥ 31.3

62.3 (76/122)

2.2 (1.4–3.5)

0.001

1.3 (0.6–2.7)

0.521

 < 31.3

42.9 (96/224)

Reference

 

Reference

 

Initial fT4 (pmol/L)

 ≥ 67.7

59.6 (90/151)

2.0 (1.3–3.1)

0.001

1.2 (0.6–2.5)

0.629

 < 67.7

42.1 (82/195)

Reference

 

Reference

 

Initial TPOAb (IU/mL)

 ≥ 67.7

53.1 (111/209)

1.4 (0.9–2.2)

0.119

  

 < 67.7

44.5 (61/137)

Reference

   

Initial TgAb (IU/mL)

 ≥ 660.0

58.6 (34/58)

1.5 (0.9–2.7)

0.139

  

 < 660.0

47.9 (138/288)

Reference

   

Initial TRAb (IU/L)

 ≥ 17.5

68.6 (81/118)

3.3 (2.1–5.3)

< 0.001

2.3 (1.4–3.9)

0.001

 < 17.5

39.9 (91/228)

Reference

 

Reference

 
  1. GO Graves’ orbitopathy, fT3 free triiodothyronine, fT4 free thyroxine, TSH thyroid stimulating hormone, TPOAb thyroid peroxidase autoantibody, TgAb thyroglobulin autoantibody, TRAb thyroid stimulating hormone receptor autoantibody, OR odds ratio, CI confidence interval
  2. aMultivariate analysis includes all characteristics with P < 0.1 in univariate analysis